Screener
Arcus Biosciences RCUS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsFairValueDisclosure.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's cash & equivalents?
- Arcus Biosciences (RCUS) reported cash & equivalents of $150M in Q2 2026.
- How has Arcus Biosciences's cash & equivalents changed year-over-year?
- Arcus Biosciences's cash & equivalents decreased by 39.5% year-over-year, from $248M to $150M.
- What is the long-term trend for Arcus Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Arcus Biosciences's cash & equivalents has grown at a 5.1% compound annual growth rate (CAGR), from $173.42M to $222M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Arcus Biosciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude